Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141919 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer
A Phase 2 study of Renal Cancers, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02141919: Active Phase 2 study of Renal Cancers, sponsored by University of Texas Southwestern Medical Center.
NCT02141919 is a Phase 2 study of Renal Cancers that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141919, a Phase 2 study of Renal Cancers, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
Primary Outcome
To evaluate if SABR to small renal tumors is able to eliminate its growth and viable tumor.
Conditions Studied
Interventions
- RADIATION Stereotactic Ablative Radiation Therapy
Study Locations (1)
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT02141919 still lists
NCT02141919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Renal Cancers appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Ablative Radiation Therapy is the first listed.
NCT02141919 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02141919 about?
NCT02141919 is a clinical study titled "Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer". The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
What is the current status of trial NCT02141919?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT02141919 study?
This clinical trial studies the following conditions: Renal Cancers.
What interventions are being tested in trial NCT02141919?
The interventions under investigation include: Stereotactic Ablative Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02141919?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141919 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02141919's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia